Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages

Pharmacological Research

Volumn 62, Issue 3, 2010, Pages 265-270

  Costa, Sara ^a   Zimetti, Francesca ^a   Pedrelli, Matteo ^a   Cremonesi, Giovanni ^b   Bernini, Franco ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Cytokine; Endothelial cell; Macrophage; Manidipine

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MANIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIPOPHILICITY; MACROPHAGE; PRIORITY JOURNAL; CELL LINE; CELL SURVIVAL; IMMUNOLOGY;

CALCIUM CHANNEL BLOCKERS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DIHYDROPYRIDINES; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MACROPHAGES; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954143701     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.03.004     Document Type: Article

References (38)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
2. Cybulsky M.I., Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
3. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008, 103:398-406.
4. Swirski F.K., Libby P., Aikawa E., Alcaide P., Luscinskas F.W., Weissleder R., et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007, 117:195-205.
5. Rus H.G., Vlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996, 127:263-271.
6. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Clin Exp Hypertens 1996, 18:489-499.
7. Henry P.D., Bentley K.I. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981, 68:1366-1369.
8. Henry P.D. Atherogenesis, calcium and calcium antagonists. Am J Cardiol 1990, 66:3I-6I.
9. Paoletti R., Bernini F., Corsini A., Soma M.R. The antiatherosclerotic effects of calcium antagonists. J Cardiovasc Pharmacol 1995, 25(Suppl. 3):S6-S10.
10. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000, 102:1503-1510.
11. Zanchetti A., Bond M.G., Hennig M., Neiss A., Mancia G., Dal Palu C., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
12. Bernini F., Canavesi M., Bernardini E., Scurati N., Bellosta S., Fumagalli R. Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. Br J Pharmacol 1997, 122:1209-1215.
13. Canavesi M., Baldini N., Leonardi A., Sironi G., Bellosta S., Bernini F. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 2004, 44:416-422.
14. Cominacini L., Garbin U., Fratta Pasini A., Paulon T., Davoli A., Campagnola M., et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997, 15:1633-1640.
15. Cavalieri L., Cremonesi G. Metabolic effects of manidipine. Am J Cardiovasc Drugs 2009, 9:163-176.
16. Havel R.J., Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995, 332:1491-1498.
17. Basu S.K., Goldstein J.L., Anderson G.W., Brown M.S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A 1976, 73:3178-3182.
18. Ronda N., Haury M., Nobrega A., Kaveri S.V., Coutinho A., Kazatchkine M.D. Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol 1994, 6:1651-1660.
19. Favari E., Bernardini E., Bernini F., Mazza P., Zani F. Cellular toxicity of N-substituted 2,2'-dicarboxamidodiphenyldisulphides with high antimicrobial activity. Pharmacol Res 1999, 40:429-434.
20. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978, 87:206-210.
21. Ronda N., Bernini F., Giacosa R., Gatti R., Baldini N., Buzio C., et al. Normal human IgG prevents endothelial cell activation induced by TNFalpha and oxidized low-density lipoprotein atherogenic stimuli. Clin Exp Immunol 2003, 133:219-226.
22. Cominacini L., Garbin U., Pasini A.F., Davoli A., Campagnola M., Pastorino A.M., et al. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens 1998, 16:1913-1919.
23. Terkeltaub R., Banka C.L., Solan J., Santoro D., Brand K., Curtiss L.K. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994, 14:47-53.
24. Crisafulli C., Galuppo M., Cuzzocrea S. Effects of genetic and pharmacological inhibition of TNF-alpha in the regulation of inflammation in macrophages. Pharmacol Res 2009, 60:332-340.
25. Cignarella A., Minici C., Bolego C., Pinna C., Sanvito P., Gaion R.M., et al. Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutr Metab Cardiovasc Dis 2006, 16:322-329.
26. Collins T., Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107:255-264.
27. Liu G., Park Y.J., Abraham E. Interleukin-1 receptor-associated kinase (IRAK)-1-mediated NF-kappaB activation requires cytosolic and nuclear activity. FASEB J 2008, 22:2285-2296.
28. Trakala M., Arias C.F., Garcia M.I., Moreno-Ortiz M.C., Tsilingiri K., Fernandez P.J., et al. Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol 2009, 39:810-819.
29. Kim Y.M., Lee B.S., Yi K.Y., Paik S.G. Upstream NF-kappaB site is required for the maximal expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus lipopolysaccharide-induced RAW 264.7 macrophages. Biochem Biophys Res Commun 1997, 236:655-660.
30. Shima E., Katsube M., Kato T., Kitagawa M., Hato F., Hino M., et al. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens 2008, 21:78-84.
31. Martin-Ventura J.L., Munoz-Garcia B., Blanco-Colio L.M., Martin-Conejero A., Madrigal-Matute J., Vega M., et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl 2008, S71-S74.
32. Zanchetti A. Closing remarks: current position of calcium channel antagonists in hypertension-the role of manidipine. Drugs 2005, 65(Suppl. 2):40-42.
33. Tan H.W., Xing S.S., Bi X.P., Li L., Gong H.P., Zhong M., et al. Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. Acta Pharmacol Sin 2008, 29:1051-1059.
34. Eickelberg O., Roth M., Mussmann R., Rudiger J.J., Tamm M., Perruchoud A.P., et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999, 99:2276-2282.
35. Caron G., Ermondi G., Damiano A., Novaroli L., Tsinman O., Ruell J.A., et al. Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine. Bioorg Med Chem 2004, 12:6107-6118.
36. Uesawa Y., Mohri K. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. Yakugaku Zasshi 2008, 128:117-122.
37. Toba H., Shimizu T., Miki S., Inoue R., Yoshimura A., Tsukamoto R., et al. Calcium [corrected] channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res 2006, 29:105-116.
38. Naito Y., Shimozawa M., Manabe H., Nakabe N., Katada K., Kokura S., et al. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol 2006, 546:11-18.